DescriptionSources: Marieb E (2014). Anatomy & physiology. Glenview, IL: Pearson Education, Inc. ISBN 978-0-321-86158-0.Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/26512
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204485Orig1s000lbl.pdf
Sources: Marieb E (2014). Anatomy & physiology. Glenview, IL: Pearson Education, Inc. ISBN 978-0-321-86158-0.
Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/26512
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204485Orig1s000lbl.pdf
Argipressin is a neurohypophysial hormone from the vasopressin hormone family. Its two primary functions are to retain water in the body and to constrict blood vessels. The antidiuretic action of Argipressin is ascribed to increase in reabsorption of water by the renal tubules. Argipressin can cause contraction of smooth muscle of the gastrointestinal tract, gall bladder, urinary bladder and all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins. Agripressin for injections is used for use in diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices. In addition, argipressin is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
CNS Activity
Curator's Comment: As a neurotransmitter and/or neuromodulator VP can modulate CNS autonomic systems controlling heart rate, arterial blood pressure, respiration rate, and sleep patterns, however, physiological significance is not understood. VP may also have an effect on certain learned behaviors, in the development of some complex social problems, and in the pathogenesis of complex psychiatric diseases such as depression.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P37288 Gene ID: 552.0 Gene Symbol: AVPR1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
0.24 nM [EC50] | ||
Target ID: P47901 Gene ID: 553.0 Gene Symbol: AVPR1B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
0.05 nM [EC50] | ||
Target ID: P30518 Gene ID: 554.0 Gene Symbol: AVPR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
4.3 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Argipressin 20 IU/ml Solution for Injection Approved UseFor use in diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices. |
|||
Primary | Argipressin 20 IU/ml Solution for Injection Approved UseFor use in diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices. |
|||
Primary | VASOSTRICT Approved UseTo increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. Launch Date1.39760645E12 |
|||
Palliative | PITRESSIN Approved UseVasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus |
|||
Diagnostic | PITRESSIN Approved UseVasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus. |
PubMed
Title | Date | PubMed |
---|---|---|
Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. | 1994 Feb 4 |
|
Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. | 1995 |
|
1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. | 1997 Jun 1 |
|
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. | 1997 Oct |
|
Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. | 1997 Oct 17 |
|
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. | 2000 Oct |
|
[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. | 2002 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/26512
For treatment of diabetes insipidus: A dose of 0.25ml to 1ml (5 to 20 units) by subcutaneous or intramuscular injection every four hours. For the initial control of variceal bleeding Argipressin should be given intravenously. Argipressin, 20 units diluted in 100ml dextrose 5% w/v may be infused over a 15 minute period.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787
Agonist activity of compound at the human vasopressin V1aR was determined in a reporter gene assays (RGA) in HEK293 cells by transiently cotransfecting recombinant vasopressin V1aR expression vectors and the reporter plasmid containing a luciferase gene under the control of NFAT response elements (NFAT-luciferase). Argipressin activates V1aR with EC50 of 0.24 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
26928-2
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
||
|
LOINC |
3126-0
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
||
|
WHO-ATC |
H01BA01
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
||
|
LOINC |
14949-2
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
||
|
WHO-ATC |
H01BA06
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
||
|
NCI_THESAURUS |
C80212
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
||
|
WHO-VATC |
QH01BA06
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
||
|
LOINC |
13903-0
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C926
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
Y4907O6MFD
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
m11399
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | Merck Index | ||
|
9937
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
644077
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
DTXSID0048349
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
Vasopressin
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
CHEMBL2108986
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
9937
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
204-035-4
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
2168
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
Y4907O6MFD
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
SUB05082MIG
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
34543
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
113-79-1
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
1098
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
ALTERNATIVE | RxNorm | ||
|
CHEMBL373742
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
1482
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
34543
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
1711100
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
11149
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
DBSALT002464
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
DB00067
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
SUB20776
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
2810
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
D001127
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
SUB05561MIG
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY | |||
|
100000086618
Created by
admin on Fri Dec 15 16:09:11 UTC 2023 , Edited by admin on Fri Dec 15 16:09:11 UTC 2023
|
PRIMARY |
ACTIVE MOIETY